SWK Holdings Corporation (SWKH)
NASDAQ: SWKH · IEX Real-Time Price · USD
17.25
-0.44 (-2.49%)
At close: Apr 22, 2024, 4:00 PM
17.30
+0.05 (0.29%)
After-hours: Apr 22, 2024, 5:24 PM EDT

Company Description

SWK Holdings Corporation, offers specialty finance and asset management services in the United States.

It operates in two segments, Finance Receivables and Pharmaceutical Development. The Finance Receivables segment provides customized financing solutions to a range of life science companies, including companies in the biotechnology, medical device, medical diagnostics and related tools, animal health, and pharmaceutical industries, as well as institutions and inventors.

This segment also offers non-discretionary investment advisory services to institutional clients in separately managed accounts to invest in life science finance.

The Pharmaceutical Development segment provides customers pharmaceutical development, formulation, and manufacturing services, as well as formulation solutions built around its proprietary oral drug delivery technologies, the Peptelligence platform.

It also offers intellectual property licensing business. The company was formerly known as Kana Software, Inc. and changed its name to SWK Holdings Corporation in December 2009.

SWK Holdings Corporation was incorporated in 1996 and is headquartered in Dallas, Texas.

SWK Holdings Corporation
SWK Holdings logo
Country United States
Founded 1996
IPO Date Sep 22, 1999
Industry Asset Management
Sector Financials
Employees 23
CEO Jody. D Staggs

Contact Details

Address:
5956 Sherry Lane, Suite 650
Dallas, Texas 75225
United States
Phone (214) 217-7253
Website swkhold.com

Stock Details

Ticker Symbol SWKH
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001089907
CUSIP Number 78501P203
ISIN Number US78501P2039
Employer ID 77-0435679
SIC Code 6159

Key Executives

Name Position
Jody. D Staggs Chief Executive Officer and President
David R. Earhart General Counsel and Secretary
John David Tamas Director of Underwriting

Latest SEC Filings

Date Type Title
Mar 22, 2024 8-K Current Report
Mar 21, 2024 8-K Current Report
Mar 20, 2024 10-K Annual Report
Mar 19, 2024 8-K Current Report
Feb 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 13, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 5, 2024 8-K Current Report
Nov 9, 2023 8-K Current Report
Nov 8, 2023 10-Q Quarterly Report
Oct 13, 2023 8-K Current Report